IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin® LAR
Tóm tắt
In vitro-in vivo correlation (IVIVC) analysis reveals a relationship between in vitro release and in vivo pharmacokinetic response of the drug of interest. Sandostatin LAR Depot (SLD) for endocrine tumors and acromegaly is a sustained-release formulation of octreotide, a cyclic oligomer of 8 amino acids, which prolongs therapeutic efficacy and enhances medication compliance of octreotide. Since the efficacy of SLD is dependent on the pharmacokinetic characteristics of octreotide released from a biodegradable matrix polymer, poly(lactide-co-glycolide)-glucose, of SLD, the IVIVC of SLD is critical for predicting an in vivo behavior of the octreotide. In this study, in vitro release of octreotide from SLD was investigated using the release test media each containing 0.02% or 0.5% surfactant and having different pH values of 7.4 and 5.5. In vivo pharmacokinetic profiles of SLD were determined by LC–MS/MS analysis of the systemic blood concentration of octreotide after the SLD injection to rodents. In IVIVC analysis, the Weibull model was adopted as a drug release model for biodegradable microsphere formulation. The IVIVC analyses revealed the in vitro release test condition of SLD with the highest IVIV correlation coefficient. By applying the in vitro release data to the model derived from the IVIVC analysis, pharmacokinetic parameters of SLD could be predicted with the prediction error of ± 10 ~ 15%. IVIVC analysis and pharmacokinetic prediction model of SLD in our study can be an efficient tool for the development of long-acting pharmaceutical dosage forms.
Tài liệu tham khảo
FDA. Guidance for Industry. Extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available from: X:TRANSFERGUIDANCEFINALX6FNL.PDF (fda.gov) Accessed July 27 2021.
Negrın C, Delgado A, Llabres M, Evora C. In vivo–in vitro study of biodegradable methadone delivery systems. Biomaterials. 2001;22:563. https://doi.org/10.1016/S0142-9612(00)00214-3.
Chu DF, Fu XQ, Liu WH, Liu K, Li YX. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm. 2006;325:116. https://doi.org/10.1016/j.ijpharm.2006.06.032.
Vlugt-Wensink K, De Vrueh R, Gresnigt M, Hoogerbrugge C, van Buul-Offers S, De Leede L, et al. Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. Pharm Res. 2007;24:2239. https://doi.org/10.1007/s11095-007-9433-y.
Rawat A, Bhardwaj U, Burgess DJ. Comparison of in vitro–in vivo release of Risperdal® Consta® microspheres. Int J Pharm. 2012;434:115. https://doi.org/10.1016/j.ijpharm.2012.05.006.
Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary. 2007;10(3):233. https://doi.org/10.1007/s11102-007-0044-8.
Rhee Y, Sohn MJ, Woo BH, Thanoo BC, DeLuca PP, Mansour HM. Sustained-release delivery of octreotide from biodegradable polymeric microspheres. AAPS PharmSciTech. 2011;12(4):1293. https://doi.org/10.1208/s12249-011-9693-z.
Hadar J, Skidmore S, Garner J, Park H, Park K, Wang Y, et al. Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations. J Control Release. 2019;304:75. https://doi.org/10.1016/j.jconrel.2019.04.039.
Burgess DJ, Crommelin DJ, Hussain AS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals. Eur J Pharm Sci. 2004;21(5):679. https://doi.org/10.1016/j.ejps.2004.03.001.
Martinez MN, Rathbone MJ, Burgess D, Huynh M. Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products. J Control Release. 2010;142:2. https://doi.org/10.1016/j.jconrel.2009.09.028.
Mircioiu C, Voicu V, Anuta V, Tudose A, Celia C, Paolino D, et al. Mathematical modeling of release kinetics from supramolecular drug delivery systems. Pharmaceutics. 2019;11(3):140. https://doi.org/10.3390/pharmaceutics11030140.
Anand O, Lawrence XY, Conner DP, Davit BM. Dissolution testing for generic drugs: an FDA perspective. AAPS J. 2011;13:328. https://doi.org/10.1208/s12248-011-9272-y.
Rastogi V, Yadav P, Lal N, Rastogi P, Singh BK, Verma N, et al. Mathematical prediction of pharmacokinetic parameters-an in-vitro approach for investigating pharmaceutical products for IVIVC. FJPS. 2018;4:175. https://doi.org/10.1016/j.fjps.2018.03.001.
Rawat A, Burgess DJ. USP apparatus 4 method for in vitro release testing of protein loaded microspheres. Int J Pharm. 2011;409(1–2):178. https://doi.org/10.1016/j.ijpharm.2011.02.057.
Ochi M, Wan B, Bao Q, Burgess DJ. Influence of PLGA molecular weight distribution on leuprolide release from microspheres. Int J Pharm. 2021;599: 120450. https://doi.org/10.1016/j.ijpharm.2021.120450.
Andhariya JV, Jog R, Shen J, Choi S, Wang Y, Zou Y, et al. Development of level A in vitro-in vivo correlations for peptide loaded PLGA microspheres. J Control Release. 2019;308:1. https://doi.org/10.1016/j.jconrel.2019.07.013.
Shen J, Choi S, Qu W, Wang Y, Burgess DJ. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres. J Control Release. 2015;218:2. https://doi.org/10.1016/j.jconrel.2015.09.051.
Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28:43. https://doi.org/10.1016/S0169-409X(97)00050-1.
Zheng Z, Seo H, Kwak HJ, Kim KY, Ahn JH, Bae MA, et al. Pharmacokinetic characterization of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor in rats. Arch Pharm Res. 2016;39:492–8. https://doi.org/10.1007/s12272-015-0702-8.
Wang Q, Liang Y, Rao T, Xie L, Ye W, Fu H, Zhou L, Xing R, Shao Y, Xiao J, Kang D, Wang G. PK study of octreotide based on LC–MS/MS combining protein precipitation and impurity extraction technique. Bioanalysis. 2015;7(7):885. https://doi.org/10.4155/bio.15.22.
Ismaiel OA, Zhang T, Jenkins R, Karnes HT. Determination of octreotide and assessment of matrix effects in human plasma using ultra high performance liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(22):2081. https://doi.org/10.1016/j.jchromb.2011.05.039.
D’Souza S. A review of in vitro drug release test methods for nano-sized dosage forms. Advances in Pharmaceutics. 2014; Article ID 304757:12 pages. https://doi.org/10.1155/2014/304757.
Tomic I, Vidis-Millward A, Mueller-Zsigmondy M, Cardot J-M. Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism. Int J Pharm. 2016;505(1–2):42. https://doi.org/10.1016/j.ijpharm.2016.03.048.
Di L., Kerns EH. Chapter 19 Pharmacokinetics. In: Di L., Kerns EH. Editors. Drug-like properties: concepts, structure design and methods form ADME to toxicity optimization, 2nd ed. Academic Press, Cambridge, USA, 2015.
Jahromi LP, Ghazali M, Ashrafi H, Azadi A. A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. Heliyon. 2020;6(2): e03451. https://doi.org/10.1016/j.heliyon.2020.e03451.
Lu Y, Kim S, Park K. In vitro-in vivo correlation: perspectives on model development. Int J Pham. 2011;418:142. https://doi.org/10.1016/j.ijpharm.2011.01.010.
Gao GF, Ashtikar M, Kojima R, Yoshida T, Kaihara M, Tajiri T, et al. Predicting drug release and degradation kinetics of long-acting microsphere formulations of tacrolimus for subcutaneous injection. J Control Release. 2021;329:372. https://doi.org/10.1016/j.heliyon.2020.e03451.
Cardot JM, Davit BM. In vitro–in vivo correlations: tricks and traps. AAPS J. 2012;14:491. https://doi.org/10.1208/s12248-012-9359-0.
Shen J, Burgess DJ. In vitro–in vivo correlation for complex non-oral drug products: where do we stand? J Control Release. 2015;219:644. https://doi.org/10.1016/j.jconrel.2015.09.052.